By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Developing and commercializing genome editing technology7.54M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States32.31M100.00%